We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
-8.71%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$93.3M
AUM Growth
+$30.2M
Cap. Flow
+$8.4M
Cap. Flow %
8.99%
Top 10 Hldgs %
81.82%
Holding
28
New
8
Increased
3
Reduced
2
Closed
7

Top Buys

Rank Stock Value
1
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
+$7.37M
2
AMGN icon
Amgen
AMGN
+$3.76M
3
GILD icon
Gilead Sciences
GILD
+$3.72M
4
AGN
Allergan plc
AGN
+$3.11M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$2.99M

Top Sells

Rank Stock Value
1
DGX icon
Quest Diagnostics
DGX
+$5.6M
2
QLTI
QLT Inc
QLTI
+$4.44M
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$3.06M
4
CYTK icon
Cytokinetics
CYTK
+$918K
5
TWM icon
ProShares UltraShort Russell2000
TWM
+$721K

Sector Composition

Rank Sector Weight
1 Healthcare 62.46%
2 Miscellaneous 37.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$827B
$22.4M 23.95%
+100,000
New +$21.8M
ANIP icon
2
ANI Pharmaceuticals
ANIP
$1.69B
$9.09M 9.74%
150,000
-50,000
-25% -$3.06M
PFE icon
3
Pfizer
PFE
$160B
$8.12M 8.7%
263,500
+79,050
+43% +$2.41M
NVLN
4
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$7M 7.5%
+831,440
New +$7.37M
ASRT
5
DELISTED
Assertio
ASRT
$6.31M 6.76%
5,833
– –
AMRI
6
DELISTED
Albany Molecular Research Inc
AMRI
$5.67M 6.08%
302,400
– –
GILD icon
7
Gilead Sciences
GILD
$185B
$5.37M 5.75%
75,000
+50,000
+200% +$3.72M
ASRT
8
CALL
DELISTED
Assertio
ASRT
$4.5M 4.83%
+4,167
New +$5.31M
GILD icon
9
CALL
Gilead Sciences
GILD
$185B
$4.3M 4.6%
60,000
+25,000
+71% +$1.86M
AMGN icon
10
Amgen
AMGN
$236B
$3.65M 3.92%
+25,000
New +$3.76M
AGN
11
DELISTED
Allergan plc
AGN
$3.15M 3.37%
+15,000
New +$3.11M
AORT icon
12
Artivion
AORT
$1.3B
$2.87M 3.08%
150,000
– –
TEVA icon
13
Teva Pharmaceuticals
TEVA
$43.8B
$2.72M 2.91%
+75,000
New +$2.99M
ARLZ
14
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$2.54M 2.72%
575,000
– –
BIS icon
15
CALL
ProShares UltraShort NASDAQ Biotechnology
BIS
$1.77M
$1.75M 1.87%
+6,250
New +$1.71M
VIXY icon
16
CALL
ProShares VIX Short-Term Futures ETF
VIXY
$212M
$1.59M 1.71%
+234
New +$1.87M
AMRN
17
Amarin Corp
AMRN
$299M
$1.39M 1.48%
22,500
– –
VIRX
18
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$543K 0.58%
4,286
– –
ZGNX
19
DELISTED
Zogenix, Inc.
ZGNX
$387K 0.41%
31,850
– –
FCSC
20
DELISTED
Fibrocell Science Inc.
FCSC
$30K 0.03%
3,185
-6,666
-68% -$71.5K
ANIP icon
21
PUT
ANI Pharmaceuticals
ANIP
$1.69B
– –
-50,000
Closed -$3.32M
CYTK icon
22
Cytokinetics
CYTK
$10.8B
– –
-100,000
Closed -$918K
DGX icon
23
Quest Diagnostics
DGX
$27B
– –
-66,208
Closed -$5.6M
TWM icon
24
ProShares UltraShort Russell2000
TWM
$44M
– –
-1,250
Closed -$721K
SEEL
25
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– -$149K
1
2

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q4 2016 Portfolio in Review

As of Q4 2016, Healthcare Value Capital held 28 positions worth $93.3M, up 48% from $63.1M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Healthcare Value Capital deployed $8.4M of net new capital in Q4 2016, opening 8 new positions and adding to 3 existing holdings. Its largest new stake was Novelion Therapeutics Inc. Common Shares: 831,440 shares worth $7M.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 85% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was ANI Pharmaceuticals, an estimated $3.06M trimmed.

  • Healthcare Value Capital's largest Q4 2016 buy was Novelion Therapeutics Inc. Common Shares: 831,440 shares worth $7M.
  • Healthcare Value Capital added most to Gilead Sciences in Q4 2016, an estimated $3.72M increase.
  • Healthcare Value Capital's biggest Q4 2016 reduction was ANI Pharmaceuticals, cutting an estimated $3.06M.
  • Healthcare Value Capital fully exited Quest Diagnostics in Q4 2016, selling an estimated $5.6M.
  • Healthcare Value Capital's ten largest holdings make up 82% of its $93.3M portfolio in Q4 2016.
  • Healthcare Value Capital opened 8 new positions and closed 7 in Q4 2016.
  • Healthcare Value Capital's portfolio value rose 48% quarter-over-quarter to $93.3M.

Based on Healthcare Value Capital's 13F filing for Q4 2016, filed 10 Feb 2017.